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Chronic histiocytic intervillositis (CHI) is a rare, but highly recurrent inflammatory placental
lesion wherein maternal macrophages infiltrate the intervillous space. Pregnancies with
CHI are at high risk of fetal growth restriction, miscarriage or stillbirth. Presently, the
diagnosis can only be made after histopathological examination of the placenta. Given
its proposed immunological etiology, current treatments include aspirin, heparin, and
immunomodulatory agents. However, the rationale for these medications is largely
based upon small case series and reports as there is a lack of larger studies
investigating treatment efficacy. Therefore, this study sought to determine whether
inclusion of immunomodulatory medications was effective at reducing the severity of
lesions and improving pregnancy outcomes in subsequent pregnancies. Thirty-three
women with a history of CHI in at least one pregnancy (index case) were identified
retrospectively through medical records. Twenty-eight participants presented with a
first subsequent pregnancy and a further 11 with a second subsequent pregnancy at
a specialist clinic for pregnancy after loss. Data on maternal demographics, medical
history, medication, pregnancy outcome, and placental pathology was collected and
compared between pregnancies. Twenty-seven (69%) subsequent pregnancies were
treated with at least one or both of prednisolone and hydroxychloroquine. Inclusion
of at least one immunomodulatory agent in treatment regimen resulted in an almost
25% increase in overall livebirth rate (61.5 vs. 86.2%). In women treated with
immunomodulatory medication a greater proportion of placentas had reduced severity
of lesions compared to those treated without (86.7 vs. 33.3%, respectively). A reduction
in CHI severity was associated with a 62.3% improvement in livebirth rate compared
to those where severity remained unchanged in relation to the index case. These
data provide preliminary evidence that the use of immunomodulatory medication in
the management of CHI improves histopathological lesions and the chance of livebirth
in subsequent pregnancies. Due to CHI’s rarity and ethical and feasibility issues,
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randomized controlled trials in affected women are challenging to conduct. As a
result, collaboration between centers is required in future to increase study sample
sizes and elucidate the mechanisms of hydroxychloroquine and prednisolone in
reducing pathology.
Keywords: placental histopathology, prednisolone, hydroxychloroquine, stillbirth, treatment, miscarriage,
outcomes
INTRODUCTION
Chronic histiocytic intervillositis (CHI), also known as chronic
intervillositis or chronic intervillositis of unknown etiology (1),
is a pregnancy disorder strongly associated with fetal growth
restriction, miscarriage, stillbirth and neonatal death (2–5).
Estimated to affect 6 in every 10,000 pregnancies over 12
weeks’ gestation, CHI is characterized by maternal macrophage
infiltration into the intervillous space of the placenta and has a
25–100% risk of recurrence in subsequent pregnancies (1, 3, 6, 7).
Many cases also exhibit marked perivillous and/or intervillous
fibrin deposition and trophoblast necrosis (8). Due to its
asymptomatic nature and a lack of reliable associated biomarkers,
currently a diagnosis of CHI can only be made following delivery
by histopathological examination of the placenta. Management
of CHI is further complicated by a lack of standardized treatment
options proven to prevent recurrence.
Owing to the presence of maternal macrophages and the
reported increased incidence in women with autoimmune
disease, CHI has been hypothesized to be a disorder of failed
maternal-fetal tolerance and excessive inflammation (9). On this
basis and due to the presence of intervillous and perivillous
fibrin, current treatments include thromboprophylactic agents
such as aspirin and low-molecular-weight heparin (LMWH)
as well as those aimed at suppressing inflammation e.g.,
corticosteroids and hydroxychloroquine (9). A systematic review
of six observational studies conducted in 2010 found no
significant improvement in pregnancy outcome with aspirin
and LMWH alone. Though a growing number of case reports
detail use of immunomodulatory agents such as prednisolone
and hydroxychloroquine (9, 10), there remains a striking lack
of larger studies supporting the efficacy of any treatment
regime in reducing severity of CHI and improving pregnancy
outcomes. Notably, a prior case series has highlighted that
women with worse obstetric histories tend to be prescribed more
therapeutic agents, despite their unproven efficacy (9). Due to
the high rate of recurrence of CHI and severe consequences
of the disorder, studies are urgently needed to determine
effective therapies.
By retrospectively identifying women with a previous
diagnosis of CHI, we aimed to investigate pregnancy outcomes
and placental pathology in subsequent pregnancies referred
to a specialist service following poor perinatal outcome,
stillbirth or neonatal death. We hypothesized, due to the
immunological nature of CHI, that treatment regimens where
immunomodulatory agents were included would decrease the
severity of the condition and consequently improve the chance
of livebirth.
MATERIALS AND METHODS
Participant Recruitment and Data
Collection
Women with a previous histopathological diagnosis of CHI
between 2009 and 2021 were identified retrospectively from
medical records at Manchester University NHS Foundation
Trust, UK. The majority of these cases were identified after
the death of a baby or late miscarriage when histopathological
evaluation of the placenta is recommended practice. In other
cases (following the birth of a live infant) the placenta is
sent away for examination for a variety of clinical indications
(e.g., FGR, fetal compromise at birth, placental abruption, and
previous late pregnancy loss). CHI was diagnosed by a specialist
perinatal pathologist in accordance with its initial description
by Labarrere and Mullen as a placental lesion consisting of
histiocytic (macrophage) infiltration into the intervillous space
(8). Data on maternal demographics, medical history including
results of tests for autoantibodies (lupus anticoagulant, anti-
phospholipid, antinuclear, and anticardiolipin antibodies) and
obstetric history were collected from the woman’s case record.
The first pregnancy diagnosed with CHI was classified as the
“index” case, with data on any subsequent pregnancies recorded
where applicable from retrospective medical records. Pregnancy
outcomes consisted of liveborn and still living, liveborn at term
and still living (>37 weeks’ gestation), miscarriage (fetal death
<24 weeks gestation, including spontaneous abortion), stillbirth
(fetal death >24 weeks gestation), and termination of pregnancy
for fetal anomaly (TOPFA). Cases of neonatal death (death of an
infant within 28 days after birth) were also recorded. Fetal growth
restriction (FGR) was defined as growth below the 3rd percentile,
and small for gestational age (SGA) as between 3rd and 10th
centile (11). Centiles were calculated for pregnancies >20 weeks’
gestation using the GROW centile calculator, for cases where
maternal demographics, pregnancy outcome and fetal sex were
known (12).
The therapeutic agents used in our service evolved over time
following publications from other researchers (3, 9, 10, 13) and
following discussion with colleagues with expertise in lupus
in pregnancy. Initially, pregnancies with CHI were managed
using Aspirin and LMWH, but this evolved to a combination
of Aspirin was given at a dose of 75–150mg once a day, a
prophylactic dose of LMWH (e.g., Tinzaparin 4,500iu) once a
day, Hydroxychloroquine 200mg twice a day and Prednisolone
20mg once a day in the morning. Drug therapy was started
from a viability scan at 6–7 weeks’ gestation. Women underwent
ultrasound assessment of uterine artery Doppler at 17 weeks’
gestation, if this showed no abnormality then Prednisolone was
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reduced by 5mg per week. If there was evidence of uterine artery
notching or raised pulsatility index Prednisolone was continued
at 20mg and then uterine artery Doppler’s were reassessed after
2 weeks. If there was no improvement by 21 weeks’ gestation
the Prednisolone was reduced at this stage. Women underwent
regular ultrasound assessment of fetal growth, amniotic fluid
volume and umbilical artery Doppler after 23 week’s gestation at
a minimum frequency of 3-weekly intervals.
Where available, placental histopathology reports were
analyzed for detail on histopathological features including the
presence of villitis, increased fibrin deposition and recurrence
and severity of CHI. Change in severity of CHI in subsequent
pregnancies was in comparison to the severity of the index
case of CHI. Focal CHI without accompanying fibrin deposition
was classified as “mild,” those with accompanying fibrin as
“moderate,” and diffuse, high-grade lesions classified as “severe.”
Informed and written consent was obtained from all
study participants and ethical approval granted by the NRES
Committee North West—Greater Manchester West and NRES
Committee London—City & East.
Statistical Analysis
Statistical analysis was conducted using GraphPad Prism Version
9.1.0. Chi-square and Kruskal-Wallis tests were performed
for categorical and continuous variables, respectively. For
statistical analysis, first and second subsequent pregnancies
were combined, and pregnancy outcomes divided into liveborn
and still living or liveborn at term and still living vs. adverse
outcome (TOPFA, miscarriage, stillbirth and neonatal death).
Where sample number precluded analysis by Chi-square, Fisher’s
Exact test was performed instead. Statistical analysis of treatment
regimen was performed by dividing participants into those
which received immunomodulatory therapy (one or both of
prednisolone and hydroxychloroquine) and those without (one
or both of aspirin and heparin, or untreated).
RESULTS
Participant Demographics
Thirty-three women with a history of at least one pregnancy
affected by CHI between 2009 and 2021 were identified
retrospectively from medical records. Twenty-eight women
presented with a subsequent pregnancy and 11 of these
with a further second subsequent pregnancy. Participant
demographics, medical and obstetric history are shown in
Table 1. Four Dichorionic-Diamniotic (DCDA) twin pregnancies
were included in the study. Twenty-six women were White
British (78.8%), with a smaller proportion of Asian (n = 6)
and Black African women (n = 1). Four index CHI pregnancies
(12.1%) were conceived using ART, compared to only one
first subsequent pregnancy (3.6%) and no second subsequent
pregnancies. Underlying autoimmune disease was present in
four cases (12.1%), consisting of coeliac disease, hypothyroidism,
autoimmune thrombocytopenia, and hypermobility syndrome,
respectively. Seventeen women had been tested for antinuclear
antibodies, three of which were positive (17.7%) and 25 and
22 women had testing for anti-cardiolipin antibodies and
TABLE 1 | Demographics and obstetric and medical history of women with a
diagnosis of chronic histiocytic intervillositis (CHI).





N participants 33 28 11
N fetuses 34 30 12
Maternal age
(years)
32 (19–38) 34 (22–41) 37 (26–40)
BMI 26 (20–47) 27 (20–47) 27 (20–40)
Ethnicity
White British 26 (78.8%)
Asian 6 (18.2%)
Black African 1 (3.0%)
Lifestyle







Previous livebirths 0 (0–5)
Previous losses 0 (0–4)
Primigravida 11 (33.3%)
ART pregnancy 4 (12.1%) 1 (3.6%) 0
















Index pregnancy was defined as a participant’s first pregnancy diagnosed with
CHI by placental histopathological examination following poor outcome. Subsequent
pregnancies refer to those following diagnosis. Continuous variables are presented as
median (range) and categorical variables N (percentage). ART, assisted reproductive
technology; BMI, body mass index.
anti-phospholipid antibodies, respectively, none of which were
positive. Of 26 women tested for lupus anticoagulant, one was
positive (3.9%). Pre-existing hypertension was present in two
women (6.1%).
Pregnancy Outcomes
Outcomes of index pregnancies diagnosed with CHI and
subsequent pregnancies are listed in Table 2. The proportion of
infants born by Cesarean section increased from 27.3% (6/33) in
index pregnancies to 59.1% (13/28) and 45.5% (5/11) in first and
second subsequent pregnancies, respectively, though this was not
statistically significant. Fetal sex did not differ significantly across
pregnancies, and in two subsequent pregnancies fetal sex had not
been determined due to loss early in gestation.
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TABLE 2 | Pregnancy outcomes of index and subsequent pregnancies in women
with a diagnosis of chronic histiocytic intervillositis (CHI).





N participants 33 28 11
N fetuses 34 30 12
Cesarean section
(>24 weeks)
6 (27.3%) 13 (59.1%) 5 (45.5%)
Male fetus 13 (38.2%) 5 (53.6%) 7 (58.3%)




4 (11.8%) 21 (70.0%) 12 (100%)
Stillbirth 16 (47.1%) 1 (3.3%) 0
Miscarriage 5 (14.7%) 6 (20.0%) 0
TOPFA 5 (14.7%) 1 (3.3%) 0
Neonatal death 4 (11.8%) 1 (3.3%) 0
Gestation at
delivery (weeks)
26 (17–41) 37 (12–39) 38 (35–39)
Birthweight centile 2.8 (0–68.4) 22.8 (0.4–99.9) 23.2
(3.8–89.6)
Complications
FGR <3rd centile 13 (52.0%) 3 (13.6%) 0
SGA 3rd−10th
centile








1 (3.0%) 0 0
Index pregnancy was defined as a participant’s first pregnancy diagnosed with
CHI by placental histopathological examination following poor outcome. Subsequent
pregnancies refer to those following diagnosis. Miscarriage was defined as fetal death<24
weeks gestation, and stillbirth as fetal death >24 weeks gestation. Neonatal death refers
to the death of an infant within 28 days after birth. Continuous variables are presented
as median (range) and categorical variables N (percentage). FGR, fetal growth restriction;
SGA, small for gestational age; TOPFA, termination of pregnancy for fetal anomaly.
The outcome of subsequent pregnancy/ies improved
significantly, with 70% of first and 100% of second subsequent
pregnancies resulting in a liveborn and still living infant,
compared to 11.8% of index pregnancies (p < 0.0001). Gestation
at delivery also increased significantly across pregnancies
(p = 0.002), from a median of 26 weeks’ gestation in index
cases to 37 weeks’ gestation in first subsequent (p = 0.04)
and 38 weeks in second subsequent pregnancies (p = 0.002).
Of infants who were liveborn, rates of neonatal death were
significantly reduced from 50% (4/8) in index cases to 3.0%
(1/33) of subsequent pregnancies (p = 0.003). TOPFA occurred
in five index pregnancies (14.7%) and one first subsequent
pregnancy (3.3%), after diagnosis of skeletal dysplasia (n = 1),
severe FGR (n = 3), triploidy (n = 1) and neurological disorder
(n= 1). In one case of stillbirth occurring in an index pregnancy,
Trisomy 18 was diagnosed at post-mortem. For infants whose
birthweight centiles could be calculated, rates of FGR <3rd
TABLE 3 | Histopathology of placentas from index and subsequent pregnancies
in women with chronic histiocytic intervillositis (CHI).





N placentas 34 30 12
N placentas with
pathology reports
34 (100%) 23 (76.7%) 8 (66.7%)
CHI 34 (100%) 11 (47.8%) 2 (25.0%)
Chronic villitis 5 (14.7%) 6 (26.1%) 2 (25.0%)
Increased fibrin
deposition
18 (52.9%) 7 (30.4%) 2 (25.0%)
Small for
gestational age
7 (20.6%) 4 (17.4%) 1 (12.5%)
Index pregnancy was defined as a participant’s first pregnancy diagnosed with
CHI by placental histopathological examination following poor outcome. Subsequent
pregnancies refer to those following diagnosis. Variables are expressed as N (percentage).
centile decreased significantly between index and subsequent
pregnancies from 52.0% (13/25) to 9.1% (3/33) (p = 0.0007).
There were no significant differences in the incidence of SGA
across pregnancies. Overall birthweight centiles increased
significantly across pregnancies from a median of 2.8 in index
cases to 22.8 and 23.2 in first and second subsequent pregnancies,
respectively (p < 0.0001). In subsequent pregnancies, 23.5% of
livebirths were preterm (8/34), significantly reduced from 75.0%
(6/8) of index cases (p = 0.01). One participant was diagnosed
with gestational diabetes in their index pregnancy (3.0%), and
there were no cases of preeclampsia. Chorioamnionitis occurred
in one index case (3.0%) alongside CHI, however since CHI
recurred without infection in the participant’s subsequent
pregnancy this case was included in the study.
Placental Pathology
Findings of placental histopathology are shown in Table 3. By
design, all index pregnancies had an accompanying placental
pathology report. The number of cases with histopathological
examination of the placenta decreased to 76.7% (23/30) and
66.7% (8/12) in first and second subsequent pregnancies as a
result of placentas not having been sent for histopathological
examination. The incidence of CHI significantly decreased from
index pregnancies, with an overall recurrence rate of 41.9%
(13/31) in subsequent pregnancies (p < 0.0001). There were no
significant differences in the incidence of villitis, increased fibrin
deposition and placentas classified as small for gestational age.
Pregnancies with concurrent CHI and villitis in the placenta
exhibited no differences in outcome compared to those with
CHI alone.
The severity of CHI lesions in placentas from index and
subsequent pregnancies as determined by histopathological
examination is shown in Figure 1. Detail of CHI lesion severity
was available for 28/34 (82.4%) and 30/31 (96.8%) placentas
from index and subsequent pregnancies, respectively. Placentas
from index cases exhibited mainly mild or moderate CHI [39.3%
(11/28) and 39.3% (11/28)], followed by a smaller proportion
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FIGURE 1 | Severity of chronic histiocytic intervillositis (CHI) lesions in
placentas from index and subsequent pregnancies according to pathologist’s
report. Index CHI refers to a participant’s first pregnancy diagnosed with CHI
by placental histopathological examination following poor outcome.
Subsequent pregnancies refer to those following diagnosis.
of severe cases [21.4% (6/28). In comparison, CHI was absent
in the majority of placentas from subsequent pregnancies (60%
(18/30)], whilst 23.3% displayed mild lesions (7/30), 10.0%
moderate (3/30), and 6.7% severe (2/30). Overall, severity of CHI
was significantly reduced in subsequent pregnancies compared to
index (p < 0.0001).
Treatment Effect
Treatment regimen across pregnancies is shown in Figure 2. The
majority of index pregnancies had no medication (24/33, 72.7%),
compared to 10.7% (3/28) of first subsequent pregnancies.
No second subsequent pregnancies were untreated. In index
pregnancies, the nine treated participants were on medication
for pre-existing medical conditions or risk factors and took
aspirin alone (n = 4), in combination with LMWH (n = 4), or
hydroxychloroquine (n = 1). There was no significant difference
in the livebirth rate of index pregnancies between women on
medication and those without. In subsequent pregnancies, 69.2%
(27/39) of all participants received immunomodulatory therapy
with at least one or both of hydroxychloroquine or prednisolone,
with the majority of participants 53.9% (21/39) receiving all
four medications. All four women with a positive autoantibody
screen were treated in their subsequent pregnancies (n = 5)
with aspirin and LMWH (n = 1); aspirin, low-molecular-weight
heparin and hydroxychloroquine (n = 1); aspirin, prednisolone,
and hydroxychloroquine (n = 1) or a combination of all four
medications (n = 2). These pregnancies all resulted in the birth
of a live infant surviving past 28 days of life.
The overall rate of infants liveborn and still living (including
infants born <37 weeks’ gestation) was almost 25% higher in
women receiving immunomodulatory treatment with one or
both of hydroxychloroquine and prednisolone compared to those
without [25/29 (86.2%) vs. 8/13 (61.5%)] (Figure 3A). However,
this did not reach statistical significance due to the number
FIGURE 2 | Treatment regimen across index pregnancies with chronic
histiocytic intervillositis (CHI) and first and second subsequent pregnancies.
Index pregnancy was defined as a participant’s first pregnancy diagnosed with
CHI by placental histopathological examination following poor outcome.
Subsequent pregnancies refer to those following diagnosis. A, aspirin; H,
hydroxychloroquine; L, low-molecular-weight heparin; P, prednisolone.
of pregnancies included in the study (p = 0.11). Inclusion
of immunomodulatory medication in treatment regimen also
resulted in a 19% increase in the proportion of infants
liveborn at term (>37 weeks) (Figure 3B) [65.5% (19/29) with
immunomodulators vs. 46.2% (6/13) without], though again
this was not statistically significant. There were no significant
effects of immunomodulatory treatment on the incidence of FGR
[8.33% (2/24) with vs. 12.5% (1/8) without], SGA [12.5% (3/24)
with vs. 12.5% (1/8) without], or on overall birthweight centiles
(median 20.9 with vs. 19.5 without).
Change in CHI severity following treatment regimen is
shown in Figure 4A. 7/13 (53.8%) placentas from women
treated without immunomodulatory medication were sent for
histopathological examination, compared to 23/29 of those who
were treated with it (82.8%). Change in severity of CHI in
one subsequent pregnancy treated without immunomodulatory
medication could not be determined due to a lack of detail
on severity of the index case. The majority of remaining
placentas from pregnancies treated without immunomodulatory
medication exhibited no change in CHI severity compared to
their index case [66.7% (4/6)]. In comparison, 86.7% (20/23) of
cases treated with immunomodulators displayed a reduction in
CHI severity or a lack of recurrence (p= 0.02). Decreased severity
of CHI in subsequent pregnancies was associated with a 62.3%
increase in livebirth rate compared to pregnancies where severity
was unchanged [20/22 (90.9%) vs. 2/7 (28.6%), respectively]
(p= 0.003; Figure 4B).
DISCUSSION
These data suggest that the use of one or both of prednisolone
and hydroxychloroquine in the treatment of CHI resulted in a
reduction of disease severity and a trend toward an increase in
livebirth rate. Overall, a decrease in CHI severity was associated
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FIGURE 3 | Outcomes of subsequent pregnancies in women with a previous diagnosis of chronic histiocytic intervillositis (CHI) following treatment with or without
immunomodulators. (A) Number of pregnancies resulting in a liveborn and still living infant (including those born <37 weeks’ gestation) or adverse outcome
(miscarriage, termination of pregnancy, stillbirth, or neonatal death). (B) Number of pregnancies resulting in a liveborn and still living infant at term (>37 weeks), or
adverse outcome (miscarriage, termination of pregnancy, stillbirth, preterm birth, or neonatal death) Immunomodulatory treatment refers to a regimen including one or
both of prednisolone and hydroxychloroquine in combination with either aspirin, heparin, or both. Pregnancies without immunomodulatory treatment were untreated
or received aspirin or heparin or both.
FIGURE 4 | The effect of immunomodulatory medication in subsequent pregnancies after a diagnosis of chronic histiocytic intervillositis (CHI). (A) Change in CHI
lesion severity in pregnancies treated with or without immunomodulatory medication, compared to the participant’s first placenta diagnosed with CHI from a previous
pregnancy. Severity of CHI was determined by pathologist’s report. Immunomodulatory treatment refers to a regimen including one or both of prednisolone and
hydroxychloroquine in combination with either aspirin, heparin, or both. Pregnancies without immunomodulatory treatment were untreated or received aspirin or
heparin or both. (B) Rate of infants liveborn and still living (past 28 days of life) in subsequent pregnancies related to change in CHI severity. *p < 0.05; **p < 0.01.
Frontiers in Medicine | www.frontiersin.org 6 October 2021 | Volume 8 | Article 753220
Brady et al. Immunomodulatory Therapy in CHI
with a 62.3% reduction in pregnancy loss. These findings
suggest that management of CHI in a specialist center for
women pregnant after loss improves outcomes, with all second
subsequent pregnancies resulting in the birth of a healthy infant.
Strengths and Limitations
Previously, treatment of CHI has been informed by case
reports and small studies detailing successful pregnancy outcome
following the use of prednisolone and other immunomodulatory
agents (10), due to a lack of randomized controlled trials
informing management. Given CHI’s rarity and ethical and
feasibility issues surrounding recruitment of women with such
poor obstetric histories, it is unlikely that there will be a study
where treatment is compared to placebo or a combination of
agents known to be ineffective (e.g., aspirin and LMWH alone).
As such, case series prove invaluable in guiding the care of
women with a history of CHI. To date, this series is the largest
to investigate the efficacy of immunomodulatory medication in
the treatment of CHI and proposes a standardized protocol
of medication to increase the chance of positive outcome in
subsequent pregnancies.
Through analysis of medical records, we have been able
to follow women through subsequent pregnancies following
diagnosis of CHI and formulate a well-characterized cohort of a
rare condition. However, we recognize that women who decided
to become pregnant or became pregnant could differ from all
women who have CHI. The demographic characteristics of our
sample were similar to those from other case series (5, 14),
suggesting that this potential selection bias had not significantly
altered the nature of the sample.
In previous investigations, the rate of recurrence of CHI
and accompanying outcome in treated pregnancies has been
relatively well-documented, though there is a paucity of evidence
regarding improvement in lesion severity. For the majority of
pregnancies we included, detail of lesion severity was available
in placental pathology reports, allowing any change to be related
to an individual’s index case. To our knowledge, this is the
first time such an approach has been taken in a case series
of treated pregnancies following CHI. Here, it was shown
that although overall recurrence of CHI in participants treated
with immunomodulatory treatment did not differ significantly
compared to those treated without, the severity of lesions was
greatly reduced. This indicates that inclusion of disease severity as
an outcome in future studies on CHI may provide better insight
into treatment effect rather than simple recurrence rate alone.
Due to the retrospective nature of this study, there were
certain variables for which data was not available within medical
records. For instance, many women whose index case of
CHI occurred less recently had not received screening for all
autoantibodies as this was a more recent practice. Additionally,
the range of antibodies tested was limited, which may explain
the low incidence of autoantibodies in this cohort in comparison
to studies which looked more specifically at antibody status
and have reported incidences between 29 and 58% (9). Since
this suggestion of an autoimmune component to CHI, it has
become standard practice within our center to offer women an
antibody screen following referral. In future, this will allow better
characterization of any possible role pre-existing antibodies may
have within CHI and may inform immunosuppressive treatment
if underlying conditions are present.
Several subsequent pregnancies included were without an
accompanying placental histopathology report as a direct result
of having not been sent for examination. In all these cases,
all respective pregnancies had resulted in a livebirth. This is
suggestive that there may have been a bias toward reporting
pathology only in pregnancies resulting in poor outcome. In
addition, pathologists were informed of patient’s medical history
which may have influenced diagnosis. In response to decreased
rates of pathological examination in subsequent pregnancies,
the importance of histopathological examination following a
history of CHI is becoming increasingly recognized amongst
midwives and clinicians within our center. Consequently,
placental histopathology is now a routine requirement and is
anticipated to improve sample size for prospective studies.
Clinical Context
Though the specific effects of prednisolone and
hydroxychloroquine could not be individually determined
here, our data is suggestive that inclusion of at least one of these
medications in the treatment of CHI can significantly reduce
the severity of macrophage infiltration into the intervillous
space. Further to this, a reduction in CHI severity increased the
likelihood of a live birth. This is in line with previous evidence
that pregnancies where CHI is severe or diffuse in the placenta
are more strongly associated with poor outcome (15). Pregnancy
outcomes in CHI and severity following hydroxychloroquine
use have not been well-documented previously, although a
single study stated that four out of six pregnancies where it was
included in treatment regimen resulted in a liveborn infant (9).
Prednisolone has also in several case reports been associated
with improved pregnancy outcome and reduced severity of
both CHI and fibrin deposition compared to treatment with
aspirin or heparin alone (2, 10, 16). Within our cohort, there
was no significant difference in fibrin deposition between index
and subsequent pregnancies, and the majority did not have an
increase in fibrin noted in their pathology report. This is perhaps
unsurprising as fibrin deposition has been classified previously as
an accompanying feature which may or may not occur alongside
CHI (1).
Whilst the exact cause of pathology in CHI is unknown,
current evidence suggests that it is driven by excessive maternal
inflammation. Inflammatory features characterized so far include
the presence of partner-directed T lymphocytes and antibodies
(17) and deposition of complement in the placenta (18).
Our observation that administration of prednisolone and
hydroxychloroquine aimed at suppressing the maternal immune
response reduces CHI severity is therefore consistent with this
hypothesis. The specific mechanism of hydroxychloroquine and
prednisolone’s anti-inflammatory effects in CHI are unknown,
though in mouse and in vitro models of antiphospholipid
syndrome, it has been suggested that hydroxychloroquine is able
to reduce complement activation and antibody binding to the
syncytiotrophoblast (19). In addition, hydroxychloroquine does
not appear to have negative effects on placental explants and
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increases release of anti-inflammatory cytokine interleukin-10
(19). As complement deposition and excessive inflammation is
characteristic of CHI, further investigation into the mechanisms
of immunomodulatory therapy in the condition is warranted.
Evidence of CHI as an alloimmune condition has also
provided rationale for the use of other immunomodulatory and
immunosuppressive routes of treatment, including intravenous
immunoglobulin (IVIG) therapy, tumor necrosis factor
(TNF) antagonists, and tacrolimus (20). In a case report by
Abdulghani et al. (13), IVIG was used following the failure
of prednisolone to produce successful outcome in a previous
pregnancy, and resulted in two subsequent healthy pregnancies.
Histopathological examination of both placentas revealed that
CHI had not recurred in either case. Similarly, use of TNF
antagonist adalimumab was reported in the pregnancy of a
woman with recurrent intervillositis and has been proposed as
a possible agent in the prevention of recurrent miscarriage (21).
Though these case reports provide anecdotal evidence hinting at
the benefits of these agents, there is still a lack of larger studies to
justify their use and as such much controversy remains.
Despite the lack of comparative studies where the efficacy
of immunomodulatory medication in treating CHI has been
specifically investigated, a livebirth rate of 66.7% in 21 women
receiving various combinations of aspirin, heparin, prednisolone
and hydroxychloroquine has previously been reported by
Mekinian et al. (9). Conversely, in the only systematic review
of intervention in CHI to date, treatment was suggested to
correlate with worse outcome, with a reported livebirth rate of
30.8% (3). Here, livebirth rate with inclusion of one or both
of hydroxychloroquine and prednisolone was markedly higher
than both studies at 86.2%. Importantly, the systematic review
did not include any studies wherein hydroxychloroquine was
administered, and treatment regimen was less consistent than
that used within this case series, both of which may be factors
in the differences observed. As in the aforementioned studies,
differences in livebirth rates within this cohort were not proven
to be significantly different between treatment groups, likely due
to limited sample size considering that data did show a trend
toward statistical significance. Given that the only systematic
review is now a decade old, it is probable that an updated
study of the literature is required to better characterize treatment
combinations and their effect on pregnancy outcome.
In subsequent pregnancies, gestational age at delivery,
fetal growth, and rates of preterm birth improved greatly,
though these effects could not be significantly attributed to
immunomodulatory treatment. It is possible that this is due
to limited numbers, or an effect of treatment using LMWH
and aspirin. Adverse outcomes may also have been reduced
as a consequence of increased fetal monitoring following
specialist care after previous pregnancy loss. As there were
insufficient numbers of untreated women and all participants had
attended the specialist clinic, it was not possible to distinguish
whether these outcomes were a result of intervention or
treatment. Increased fetal monitoring is unable to influence
fetal growth, but delivery via Cesarean section showed a trend
toward increasing across subsequent pregnancies despite lacking
statistical significance. Other centers have reported low levels of
spontaneous labor in cases of CHI and early delivery of a liveborn
infant has been detailed in a case report following observations of
fetal growth plateau (9, 10). Therefore, it is possible that electing
for early delivery may have had a beneficial effect in select cases.
Recurrence rates of CHI in subsequent pregnancies vary
widely between studies and have been reported between 25
and 100% (1, 3, 7). Within this cohort, recurrence of CHI was
41.9%, though the majority of pregnancies were treated which
in 20 placentas reduced severity, some to the point where CHI
was absent. In agreement with observations made by other
groups, recurrence of CHI was not always associated with adverse
outcome (9, 22). Bos et al. in their systematic review stated
that incidence and recurrence of CHI may vary due to differing
inclusion and exclusion criteria across studies (1). A controversial
criterion noted was the exclusion of cases with chronic villitis
or villitis of unknown etiology alongside CHI. As concurrent
CHI and chronic villitis lesions have been reported in 25–47% of
placentas (15, 23), those with combined lesions were not excluded
here as they represented a similar and considerable proportion
of cases. Of particular interest was the observation that the
incidence of chronic villitis did not differ across pregnancies
and therefore seemed unaffected by intervention within the
participant group studied. In addition, though chronic villitis
is itself associated with FGR (24), outcomes of pregnancies
with concurrent CHI and chronic villitis were not significantly
different, suggesting that chronic villitis in the presence of CHI
may not have been a strong factor in adverse outcome.
CONCLUSION
The data from this retrospective study suggest that including at
least one of hydroxychloroquine or prednisolone in treatment
regimen of pregnancies following diagnosis of CHI is effective
at reducing placental lesion severity. In turn, decreased severity
of CHI improves the likelihood of livebirth in subsequent
pregnancies. From this, we propose that a standardized
treatment protocol including aspirin, heparin, prednisolone and
hydroxychloroquine may prove beneficial in the management
of CHI. Studies into the efficacy of both hydroxychloroquine
and prednisolone as well as other immunomodulatory agents
used within the condition is extremely limited, and feasibility of
randomized controlled trials in affected women is low given their
poor obstetric history. To overcome this challenge, collaboration
between centers specializing in the management of CHI is
required to increase sample sizes to allow sufficient evaluation of
treatment regimen.
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